Previous 10 | Next 10 |
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up to 98% with reductions of up to 81% persisting at 150 days Results to be ...
Data to be presented by Professor of Cardiovascular Medicine at the Cleveland Clinic, Steven Nissen, MD, on Sunday April 3, 2022 Silence on-track to report topline data from the SLN360 phase 1 single-ascending dose study this quarter Silence Therapeutics plc, Nasdaq:...
Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, is pleased to announce that Dr. Marie Wikström Lindholm, S...
Image source: The Motley Fool. Silence Therapeutics plc (NASDAQ: SLN) Q2 2021 Earnings Call Aug 12, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Silence Therapeutics plc (SLN) Q2 2021 Earnings Call Transcript
Silence Therapeutics plc (SLN) Q2 2021 Earnings Conference Call August 12, 2021, 08:00 AM ET Company Participants Gem Hopkins - Head, Investor Relations and Corporate Communications Mark Rothera - President and CEO Craig Tooman - Chief Financial Officer Giles Campion - EVP, Head of R&D an...
The following slide deck was published by Silence Therapeutics plc in conjunction with their 2021 Q2 earnings call. For further details see: Silence Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation
Silence Therapeutics (SLN) received the remaining $40M from AstraZeneca (AZN) due as part of AstraZeneca's $80M cash and equity investment for the siRNA collaboration announced in March 2020.The $40M is included in Silence’s reported £97.5M proforma cash balance at 2020 year-...
Silence Therapeutics (SLN) announces positive topline data from the GEMINI phase 1 study of SLN124 in healthy volunteers. SLN124 is in development for the treatment of iron-loading anemia conditions, thalassemia and myelodysplastic syndrome ((MDS)). The phase 1 study evaluated the safety...
Image source: The Motley Fool. Silence Therapeutics Plc (NASDAQ: SLN) Q4 2020 Earnings Call Mar 30, 2021 , 8:00 a.m. ET Continue reading For further details see: Silence Therapeutics Plc (SLN) Q4 2020 Earnings Call Transcript
The following slide deck was published by Silence Therapeutics plc in conjunction with their 2020 Q4 earnings call. For further details see: Silence Therapeutics plc 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...